首页> 外文期刊>Endocrine-related cancer >Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival
【24h】

Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival

机译:营养性酰胺化肽及其受体在良性和恶性嗜铬细胞瘤中的表达:肾上腺髓质素RDC1受体的高表达及其在肿瘤细胞存活中的意义

获取原文
           

摘要

Pheochromocytomas are catecholamine-producing tumors which are generally benign, but which can also present as or develop into malignancy. Molecular pathways of malignant transformation remain poorly understood. Pheochromocytomas express various trophic peptides which may influence tumoral cell behavior. Here, we investigated the expression of trophic amidated peptides, including pituitary adenylate cyclase-activating polypeptide (PACAP), neuropeptide Y (NPY), and adrenomedullin (AM), and their receptors in benign and malignant pheochromocytomas in order to assess their potential role in chromaffin cell tumorigenesis and malignant transformation. PACAP, NPY, and AM are expressed in the majority of pheochromocytomas studied; NPY exhibiting the highest mRNA levels relative to reference genes. Although median gene expression or peptide levels were systematically lower in malignant compared to benign tumors, no statistically significant difference was found. Among all the receptors of these peptides that were analyzed, only the AM receptor RDC1 displayed a differential expression between benign and malignant pheochromocytomas. This receptor exhibited a fourfold higher expression in malignant than in benign tumors. AM and stromal cell-derived factor 1, which has also been described as a ligand for RDC1, increased the number of human pheochromocytoma cells in primary culture and exerted anti-apoptotic activity on rat pheochromocytoma PC12 cells. In addition, RDC1 gene silencing decreased the number of viable PC12 cells. This study shows the expression of several trophic peptides and their receptors in benign and malignant pheochromocytomas, and suggests that AM and its RDC1 receptor could be involved in chromaffin cell tumorigenesis through pro-survival effects. Therefore, AM and RDC1 may represent valuable targets for the treatment of malignant pheochromocytomas.
机译:嗜铬细胞瘤是产生儿茶酚胺的肿瘤,通常是良性的,但也可能表现为恶性或发展为恶性肿瘤。恶性转化的分子途径仍然知之甚少。嗜铬细胞瘤表达各种营养肽,可能影响肿瘤细胞的行为。在这里,我们研究了营养性酰胺化肽的表达,包括垂体腺苷酸环化酶激活多肽(PACAP),神经肽Y(NPY)和肾上腺髓质素(AM)及其受体在良性和恶性嗜铬细胞瘤中的表达,以评估其在潜在的嗜铬细胞瘤中的作用。嗜铬细胞的肿瘤发生和恶变。 PACAP,NPY和AM在研究的大多数嗜铬细胞瘤中均有表达。相对于参考基因,NPY表现出最高的mRNA水平。尽管与良性肿瘤相比,恶性肿瘤的中位基因表达或肽水平总体上较低,但未发现统计学上的显着差异。在所分析的这些肽的所有受体中,只有AM受体RDC1在良性和恶性嗜铬细胞瘤之间显示出差异表达。该受体在恶性肿瘤中的表达比在良性肿瘤中高四倍。 AM和基质细胞衍生因子1(也已被描述为RDC1的配体)增加了原代培养中人嗜铬细胞瘤细胞的数量,并对大鼠嗜铬细胞瘤PC12细胞发挥了抗凋亡活性。此外,RDC1基因沉默减少了存活的PC12细胞的数量。这项研究显示了多种营养肽及其受体在良性和恶性嗜铬细胞瘤中的表达,并表明AM及其RDC1受体可能通过促存活作用参与嗜铬细胞的肿瘤发生。因此,AM和RDC1可能代表了治疗恶性嗜铬细胞瘤的重要靶标。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号